Elan

Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

Alkermes Earnings Seen Rising, But Sales Uncertain

Royalty Pharma Raises Elan Corporation PLC Bid to $12.50 a Share in Cash

Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray

Royalty Pharma Lifts Elan Bid To $12.50 Per Share - Update

Elan’s Response to Royalty Pharma Announcement

Elan Transformation Continues, but We Remain Skeptical of Deal Values

Royalty Pharma ups offer for Elan to $12.50 per share in cash

Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash

Elan Corp (ELN) Plans Strategic Change of Company; Proposes $200M Buyback